Found 11 matching trials
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
PHASE1This is an open-label trial to evaluate the safety, tolerability and immuno...
Location
Central Kentucky Research Associates
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
PHASE1This is an open label, phase 1 clinical trial of an intra-dermal booster do...
Location
Multiple Locations
Therapeutic Vaccination in Treated HIV Disease
PHASE1The central premise of our program is that durable control of HIV in the ab...
Location
University of California, Los Angeles
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC
PHASE1This is a single-arm, open-label, multi-site Phase I/IIa study of a persona...
Status
Active Not Recruiting
Location
Johns Hopkins Hospital
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
PHASE1This is a Phase 1b/2a, open-label, multi-center study to evaluate the safet...
INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
PHASE1This is a Phase 1/2 open-label, multicenter trial to evaluate the safety, t...
Location
Mayo Clinic Arizona
dMAbs for Prevention of COVID-19
PHASE1This is a Phase 1, open-label, single center, dose escalation study to eval...
Location
University of Pennsylvania
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
PHASE2This is a Phase 2/3, randomized, placebo-controlled, multi-center trial to ...
Location
Synexus Clinical Research US, Inc - Phoenix Southeast
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
PHASE1This is a randomized and double-blinded within study group, placebo-control...
Location
The Center for Pharmaceutical Research
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
PHASE1Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy...
Status
Active Not Recruiting